In the last few years oncologists have had to revise their ideas about the role of chemotherapy in osteosarcoma, and at the present time there is what might appear to be a complex and technical debate going on about the value of chemotherapy. In fact the problem is simple. It is that in spite of clinical evidence from some authorities that survival' is prolonged by cytotoxic drugs, we do not know for certain if this is the case or, if it is, whether the effect is insubstantial, not justifying the great expense and toxicity of treatment. To understand this interesting controversy, we need to look at the historical development of chemotherapy in this disease.
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Background to the development of modern chemotherapy In the 1960s a variety of cytotoxic drugs were used for treatment of metastatic osteosarcoma, On the whole responses were infrequent and, even when they did occur, were seldom either complete or long-lasting. Thus Evans (1961) at first reported a 23% response rate with mitomycin C but later could not confirm this (Evans et al. 1969) . Sullivan et al. (1963) showed that occasional responses could be obtained with alkylating agents such 'as melphalan, and cyclophosphamide also occasionally produced responses (Finklestein et al. 1969) . These agents, when used as adjuvants to surgery following amputation, probably did not increase disease-free survival although no assessment of their effectiveness, by randomized comparison with an untreated control group, was made.
In the early 1970s two new agents were introduced which were to become the mainstay of the chemotherapy regimens now in use. Adriamycin was shown to be effective in a wide variety of paediatric tumours including soft tissue sarcoma, and was soon tried in osteosarcoma. Cortes et al. (1972) reported responses in 4 out of 13 cases, and Gottlieb et al. (1975) , in a later review of the world literature, put the response rate at about 22%. Although the results with the drug could hardly be described as dramatic, it was one of the most effective agents tested at that time. The other agent was methotrexate used in very high doses. This way of giving what is one of the oldest cytotoxic drugs followed upon the work of Djerassi (1967) in the treatment of acute leukaemia and other diseases. He had shown that it was possible to give very high doses of the drug with folinic acid rescue, and that responses might then be seen in tumours which were resistant to the drug at conventional doses. Jaffe (1972) then showed that regression of metastatic osteosarcoma could occur with very high doses (up to 7.5 gjm 2 ) . A policy of dose escalation could be adopted in which the dose was gradually increased and responses could occur at, for example, 7 gjm 2 , in tumours which did not respond to 4 gjm 2 • It has never been clear why the tumour should respond to these astonishingly high doses while not doing so at dose levels which were already over a hundred times greater than those given conventionally. Rosen et al. (1974) combined highdose methotrexate (HD MTX) with adriamycin for the treatment of metastatic disease in 13 children, some of whom had the primary tumour still in situ. Few of the cases showed regression of metastases or primary tumour, but several had relief of pain and a fall in alkaline phosphatase.
Other drug combinations were tried in metastatic disease. Mitomycin C, melphalan and vincristine appeared ineffective (Jaffe et al. 1971 ), but some short-lived responses were seen with bleomycin, cyclophosphamide and actinomycin D (BCD) (Mosende et al. 1977) .
High-dose methotrexate (HD MTX) was then used as an adjuvant after amputation in patients free of metastases, both with vincristine (which was probably valueless) and with adriamycin. In what was at the time an exciting report, Jaffe et al. (1974) showed that the disease-free survival of 12 patients treated with HD MTX was vastly superior to that of a historical control group. This report was among the first of a series of papers describing the effects of adjuvant chemotherapy in the disease. Sutow et al. (1978) reported a 55% survival with the use of a muitidrug regimen (CONPADRI) later including methotrexate (COMPADRI). At the Sloan-Kettering Cancer Centre, Rosen and co-workers began a series of adjuvant studies initially based on HD MTX, cyclophosphamide and adriamycin. They used these agents preoperatively in an attempt to prepare the tumour for prosthetic replacement of bone. At first the drugs were continued for one year postoperatively. They showed that control of the primary disease was usually possible (Rosen et al. 1976 ) and that necrosis of the tumour was often seen histologically when it was removed. This approach was then continued, with the chemotherapy gradually being intensified but shortened in duration. Reporting on 6 years of results in 1979, the Sloan-Kettering group stated that these drugs alone were insufficient since the 3-year survival was only 65% (Rosen et al. 1979) . They therefore increased the methotrexate to a weekly regimen (instead of 6-weekly) and added BCD to the treatment. In an addendum to the paper which summarized these results they stated that, with a median follow-up time of 22 months, 88% of 61 patients were disease-free. They also introduced the concept of grading the degree of response histologically and seemed to show that good responses, as judged by tumour necrosis, were associated with a better prognosis.
At the same time there began to appear disquieting reports that HD MTX was not as effective as had previously been thought. In an update of their 1974 paper, Jaffe et al. (1978) reported that 60% of the 12 patients had relapsed by 5 years and 4 of the 5 disease-free patients had parosteal osteosarcoma -a much more benign disease. This suggested that, if HD MTX was doing anything, it was delaying metastases, not preventing them. This conclusion was strengthened by a report from Rosenberg et al. (1979) from the National Cancer Institute. They treated 39 patients with HD MTX, increasing the dose to 250 mg/kg every 3 weeks. When the results were analysed and compared with historical controls matched for age, tumour site and histological grade, no evidence could be found for an effect ofHD MTX.
There were other developments which introduced further complexity into the drug regimens. Firstly, Jaffe et al. (1977) claimed that better responses were seen with HD MTX given weekly rather than 3-weekly, a suggestion supported by Rosen et al. (1979) . As experience was gained with the drug and its administration, it became possible to give these huge doses without undue toxicity. The availability of quick and reliable serum methotrexate measurements led to considerable precision in anticipating and avoiding toxicity. Secondly, a new agent, cisplatin, became available and was shown to be active in metastatic disease (Ochs et al. 1978) .
We now come to the present day and to consider what the value of adjuvant chemotherapy has been. I shall do this by first presenting the results of fairly typical aggressive adjuvant chemotherapy regimens and then considering the factors other than chemotherapy which might have contributed to the results.
Recent chemotherapy results
Several studies are now showing 2-3 year disease-free survival rates greater than 70%. Bleyer et al. (1982) reported on 22 patients treated mainly with methotrexate and adriamycin and found a 67% disease-free survival at 3 years. have reported on their TIO protocol in which patients are treated with weekly HD MTX and one cycle of BCD and adriamycin. Following surgery (either amputation or endoprosthesis) they receive either more HD MTX, BCD and adriamycin if the tumour has shown a good histological response, or cisplatin, adriamycin and BCD if the response is poor. In both groups, oyer 90% of patients are disease-free at 2 years, but because of the design of the study it is not possible to say if the change in chemotherapy is essential. Nevertheless, these are impressive and unrivalled short-term results. The combination of cisplatin and adriamycin in the small study reported by Ettinger et al. (1981) has also shown a 2-year survival of over 80%.
Rosen attributes the steady improvement in his results to the better use of chemotherapy, especially in the way in which HD MTX is given. He stresses that the dose is critical and cites instances in which, for example, patients have failed to respond to intermittent doses up to 10 g, but have had complete responses to intensive weekly doses of 14 g. He also regards the change of chemotherapy on the basis of histological response as a factor in improving results. He regards it as 'perfectly clear that chemotherapy is effective in increasing the cure rate for osteogenic sarcoma' (my italics) (Rosen & Nirenberg 1982) .
Other factors influencing disease-free survival It is perhaps obvious, but sometimes forgotten, that disease-free survival is not the same as cure. If a treatment only delays the appearance of metastases, then disease-free survival is prolonged but long-term survival is ultimately the same. The effect of the treatment is therefore exciting and apparent in the first few years but less so as time goes by. This is exactly what happened to Jaffe's early results. Will the same thing happen to the latest, early results? We have seen in other tumours more sensitive to chemotherapy than osteosarcoma, such as breast cancer and small cell lung cancer, that chemotherapy has prolonged the disease-free interval without affecting survival greatly. Why should not the same thing happen with osteosarcoma? On the other hand one can agree that even if survival is ultimately only improved by 10-20%, this will be worthwhile; and a long disease-free interval is in itself a useful thing for patients provided the toxicity of treatment is not too great. The problem is that unless a clear difference in long-term survival is seen, we shall not know if chemotherapy has contributed at all because other factors are at work to influence prognosis.
The advent of CT scanning of the lung has allowed the early detection of pulmonary metastases and this means that patients who would have been included in studies may now be left out because of demonstrable metastatic disease. This clearly introduces a bias in favour of better cases where metastasis has not occurred.
There is also evidence that the old figures showing that only 20% of patients survived 5 years are now not representative and that surgery alone~ay be as~ociate~with a 40-50% 5year survival. Perhaps this is because of better case selection but, If true, It makes the recent claims hard to evaluate.
The Mayo Clinic is the only institution to car~y ?ut a controlled c~m~arison of surgery and chemotherapy against surgery alone. Preliminary statements indicate that at the moment there is no difference in the two arms (Edmonson et al. 1980) . Doubtless this study will be criticized by groups such as the Sloan-Kettering workers, who say that they have what they regard as excellent results because ofscrupulous attention to detail and the escalation of HD MTX dose and frequency.
Conclusion
In my view it is probable that the high-dose chemotherapy. programmes recently employed in osteosarcoma prolong the disease-free interval, but It seems to me to be unclear whether long-term survival will be improved by these regimens. It is hard to understand why the results of chemotherapy should be expected to be so much better in this disease than in other drug-resistant cancers. It seems a contradiction to state that the dose of HD MTX in an individual patient may be critical between, say, 8 g and 12 g, and yet to expect that a treatment as marginal as this will improve survival. A randomized prospective comparison against a control group treated with surgery alone is the only way that the value of chemotherapy can be assessed (Lange & Levine 1982) . Such a comparison will have to be made at those special centres skilled in the use of HD MTX, and following the same protocols as those currently being used, so as to avert any criticism that the treatment was given wrongly or in too Iowa dose. Is such a trial ethical? I believe it is. Treatment is costly, toxic and unpleasant. We need to find out if it is as effective as is claimed.
